心力衰竭患者铁缺乏的诊断标准:不同定义对患病率与预后的影响
该研究纳入2001至2019年转诊至区域诊所的4422例慢性心衰患者,评估不同铁缺乏定义下的患病率及其与预后的关系。结果显示,不同定义下铁缺乏患病率差异显著(46%-68%),且仅TSAT<20%和血清铁≤13 μmol/L与5年死亡率升高相关,而指南标准无此关联。
要点
- 指南铁缺乏标准(铁蛋白<100 ng/mL或100-299 ng/mL且TSAT<20%)患病率高达68%,但其中35%患者TSAT>20%。
- TSAT<20%和血清铁≤13 μmol/L与5年死亡率升高独立相关,而指南标准未显示预后关联。
- 铁蛋白<100 ng/mL则倾向于与较低死亡率相关(HR 0.91,P=0.09),提示炎症可能影响铁蛋白解读。
核心结论
- 不同铁缺乏定义在慢性心衰患者中得到的患病率和预后关联不一致。
- 缺乏特异性的定义可能削弱静脉铁剂的试验获益,而缺乏敏感性的定义可能排除应接受静脉铁剂的患者。
研究设计与样本
- 回顾性队列研究,纳入2001至2019年转诊至Hull LifeLab区域诊所的4422例心衰患者。
- 中位年龄75岁(范围68-82岁),60%为男性,32%为射血分数降低的心衰。
主要发现
- 46%患者TSAT<20%,48%血清铁≤13 μmol/L,57%铁蛋白<100 ng/mL,68%符合指南铁缺乏标准。
- 符合指南标准的患者中35% TSAT>20%。
- 无论何种定义,铁缺乏在女性、症状更重、贫血或射血分数保留的患者中更常见。
- TSAT<20%与5年死亡率升高相关(HR 1.27;95% CI 1.14-1.43;P<0.001)。
- 血清铁≤13 μmol/L与5年死亡率升高相关(HR 1.37;95% CI 1.22-1.54;P<0.001)。
关键数值与推荐
- 指南铁缺乏定义:血清铁蛋白<100 ng/mL,或铁蛋白100-299 ng/mL时TSAT<20%。
- TSAT<20%定义铁缺乏。
- 血清铁≤13 μmol/L定义铁缺乏。
- 血清铁蛋白<100 ng/mL定义铁缺乏。
临床怎么用
- 临床评估心衰患者铁缺乏时需注意不同定义对患病率和预后判断的影响。
- TSAT<20%或血清铁≤13 μmol/L可能提示更高的死亡风险,可辅助风险分层。
- 铁蛋白受炎症影响,解读时应结合TSAT等指标综合判断。
局限性
- 研究为单中心区域诊所队列,结果外推需谨慎。
- 未报告不同定义对静脉铁剂治疗反应的预测价值。
- 作者建议正在进行的随机试验预设亚组分析来进一步阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines on heart failure (HF) define iron deficiency (ID) as a serum ferritin <100 ng/mL or, when 100-299 ng/mL, a transferrin saturation (TSAT) <20%. Inflammation (common in HF) may hinder interpretation of serum ferritin. OBJECTIVES: This study sought to investigate how different definitions of ID affect its prevalence and relationship to prognosis in ambulatory patients with chronic HF. METHODS: Prevalence, relationship with patients' characteristics, and outcomes of various ID definitions were evaluated among patients with HF referred to a regional clinic (Hull LifeLab) from 2001 to 2019. RESULTS: Of 4,422 patients with HF (median age 75 years [range: 68-82 years], 60% men, 32% with reduced left ventricular ejection fraction), 46% had TSAT <20%, 48% had serum iron ≤13 μmol/L, 57% had serum ferritin <100 ng/mL, and 68% fulfilled current guideline criteria for ID, of whom 35% had a TSAT >20%. Irrespective of definition, ID was more common in women and those with more severe symptoms, anemia, or preserved ejection fraction. TSAT <20% and serum iron ≤13 μmol/L, but not guideline criteria, were associated with higher 5-year mortality (HR: 1.27; 95% CI: 1.14-1.43; P < 0.001; and HR: 1.37; 95% CI: 1.22-1.54; P < 0.001, respectively). Serum ferritin <100 ng/mL tended to be associated with lower mortality (HR: 0.91; 95% CI: 0.81-1.01; P = 0.09). CONCLUSIONS: Different definitions of ID provide discordant results for prevalence and prognosis. Definitions lacking specificity may attenuate the benefits of intravenous iron observed in trials while definitions lacking sensitivity may exclude patients who should receive intravenous iron. Prespecified subgroup analyses of ongoing randomized trials should address this issue.
引用
- Masini, Graham, Pellicori, et al. Criteria for Iron Deficiency in Patients With Heart Failure. J Am Coll Cardiol. 2022. PMID: 35086656. doi:10.1016/j.jacc.2021.11.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。